MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.drugpo.2022.103876

Медицинская библиотека · The International journal on drug policy · 2022

Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.

Valerio Heather, Conway Anna, Alavi Maryam, Treloar Carla, Silk David, Murray Carolyn, Henderson Charles, Amin Janaki, Read Phillip, Degenhardt Louisa, Christmass Michael, Montebello Mark, Dore Gregory J, Grebely Jason, ETHOS Engage Study Group

Наблюдательное исследованиеСтатьяПеревод в очереди

Аннотация

BACKGROUND

Awareness of hepatitis C virus (HCV) infection status among people who inject drugs (PWID) can empower people with diagnosis, enable treatment uptake, and facilitate elimination. We aimed to evaluate awareness of HCV infection status among a large national cohort of PWID in an era of unrestricted HCV treatment.

METHODS

ETHOS Engage is an observational cohort study of PWID attending drug treatment clinics and needle and syringe programs in Australia. Participants completed a questionnaire containing self-reported HCV data (including infection status: never tested, tested/unknown, no current HCV infection [HCV RNA not detectable], current HCV infection [HCV RNA detectable]) and underwent point-of-care HCV RNA testing (Xpert® HCV Viral Load Fingerstick). Awareness was defined as concordant self-reported HCV status and test result. Awareness was assessed among all participants, those with current HCV infection, and participants who reported a lifetime history of HCV treatment. Logistic regression was used to assess factors associated with awareness in these three populations.

RESULTS

Among 2,305 PWID, 65% (n=1,506) were aware of their HCV infection status (self-reported HCV status matched HCV point-of-care result). Awareness of infection status was higher among those who were not currently infected (70%, n=1,281/1,818) compared to those with current HCV infection (46%, n=225/487). After adjusting, those with current HCV infection were less likely to be aware of infection status (aOR: 0.40, 95%CI: 0.30, 0.45). Among those who reported a lifetime history of HCV treatment, 71% (n=592/829) were aware of their HCV infection status.

CONCLUSION

Among a large cohort of PWID in Australia, awareness of HCV infection status is sub-optimal, with particularly concerning levels among those with active infection. Increased and simplified testing, post-test counselling, and post-treatment monitoring is warranted.

Для цитирования: Valerio Heather, Conway Anna, Alavi Maryam, Treloar Carla, Silk David, Murray Carolyn, Henderson Charles, Amin Janaki, Read Phillip, Degenhardt Louisa, Christmass Michael, Montebello Mark, Dore Gregory J, Grebely Jason, ETHOS Engage Study Group. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.. The International journal on drug policy. 2022. DOI: 10.1016/j.drugpo.2022.103876.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.